Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8141964 | 1.00 | MAPK1 (0.39) | MAPK1NPSR1L3MBTL1CYP3A4CYP2D6 | |
| SCHEMBL10689947 | 1.00 | MAPK1 (0.39) | MAPK1NPSR1L3MBTL1CYP3A4CYP2D6 | |
| SCHEMBL12633006 | 1.00 | MAPK1 (0.39) | MAPK1NPSR1L3MBTL1CYP3A4CYP2D6 | |
| SCHEMBL15483027 | 0.94 | L3MBTL1 (0.35) | MAPK1NPSR1L3MBTL1 | |
| SCHEMBL18840312 | 0.94 | L3MBTL1 (0.35) | MAPK1NPSR1L3MBTL1 | |
| SCHEMBL14790100 | 0.94 | L3MBTL1 (0.35) | MAPK1NPSR1L3MBTL1 | |
| SCHEMBL31741256 | 0.94 | L3MBTL1 (0.35) | MAPK1NPSR1L3MBTL1 | |
| SCHEMBL6123055 | 0.82 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL18840314 | 0.78 | MAPK1 (0.34) | MAPK1NPSR1L3MBTL1ALDH1A1 | |
| SCHEMBL1132322 | 0.78 | MAPK1 (0.32) | MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-06-27 | — | — | US | disclosed |
| US-9989849-B2 | Chemically amplified resist material and resist pattern-forming method | JSR CORPORATION (JP) | 2018-06-05 | — | — | US | disclosed |
| US-20170131634-A1 | CHEMICALLY AMPLIFIED RESIST MATERIAL AND RESIST PATTERN-FORMING METHOD | JSR CORPORATION (JP) | 2017-05-11 | — | — | US | disclosed |
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-03-17 | — | — | US | disclosed |
| US-4761491-A | Preparation of 2-substituted-1,3-dioxacycloalkanes from diols and diunsaturated ethers | THE DOW CHEMICAL COMPANY (US) | 1988-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050058725-A1 | Combination therapy including a matrix metalloproteinase inhibitor and an antineoplastic agent | MMP3, MMP10, MMP25 | MAPK1 3095/4885NPSR1 3589/4885L3MBTL1 1485/4885 |
| US-11687000-B2 | Sulfonium compound, chemically amplified resist composition, and patterning process | ETV6, PKD1, PKD2 | MAPK1 1296/4885NPSR1 3756/4885L3MBTL1 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.